Navigation Links
Cardium Reports on Transdel Transaction
Date:7/28/2011

cialization, partnering and other economic monetizations.  Cardium's investment portfolio includes the Tissue Repair Company and Cardium Biologics, medical technology companies primarily focused on the development of innovative therapeutic products for wound healing, bone repair, and cardiovascular indications.  In July 2009, Cardium completed the sale of its InnerCool Therapies medical device business to Royal Philips Electronics, the first asset monetization from the Company's biomedical investment portfolio.  News from Cardium is located at www.cardiumthx.com.

Forward-Looking Statements

Except for statements of historical fact, the matters discussed in this press release are forward looking and reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond our control and may cause actual results to differ materially from stated expectations.  For example, there can be no assurance that the proposed Transdel transaction or any other transactions under consideration will be completed; that our stockholder's equity can be increased and maintained to a sufficient level to satisfy ongoing compliance with the requirements of our listing stock exchange; that Ketotransdel can be successfully developed to result in an FDA Section 505(b)(2) registered product in the United States; that results or trends observed in one clinical study or procedure will be reproduced in subsequent studies or procedures, or that clinical studies even if successful will lead to product advancement or partnering; that the U.S. Food and Drug Administration (the "FDA") will grant marketing clearance of Ketotransdel or other product candidates or that we or a partner can successfully introduce these or additional products into topical NSAID markets in the U.S. or elsewhere; that Ketotransdel or other product candidates will prove to be sufficiently safe
'/>"/>

SOURCE Cardium Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cardium Announces Market Introduction of New Alena™ Clinical Strength Carb Blocker to Expand the MedPodium Healthy Lifestyle Product Line
2. Cardium Announces Plans to Acquire Transdel Pharmaceuticals Phase 3 Topical Analgesic and Cosmeceutical Business Assets
3. Cardium Announces Cedars-Sinai Heart Institute as the SPECT Imaging Core Lab for the Recently Announced Generx® Phase 3 Clinical Registration Study in the Russian Federation
4. Cardium Presents First Quarter 2011 Financial Results and Reports on Near-Term Milestones
5. Cardium to Present at OneMedForum San Francisco 2011 Conference
6. Cardium Announces New Research Findings: Excellagen Product Candidate Activates Platelet Release of PDGF, an Important Growth Factor Fundamental to the Wound Healing Process
7. Cardium Reports on Fourth Quarter and Year-End 2009 Financial Results and Recent Developments
8. Cardium Presents at Tenth Annual Wound Healing: Science and Industry Conference on Matrix Wound Healing Clinical Development
9. Cardium Files FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Topical Gel and ExcellagenFX(TM) Flowable Collagen Protein-Based Matrix for Diabetic, Pressure and Venous Ulcers and Other Dermal Wounds
10. Cardium Reports Non-Healing Wounds Continue to Challenge Patients and Healthcare Providers
11. Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014  Manufacturers, suppliers and distributors of innovative medical-related ... their most important business assets, intellectual property (IP). ... Because of the highly-competitive nature of the ... the most litigious industry sectors of cases involving ...
(Date:1/15/2014)...  Echo Therapeutics, Inc. (Nasdaq: ECTE ) ("Echo"), ... as a non-invasive, wireless continuous glucose monitoring system, today ... and Interim CEO of Echo Therapeutics, will present at ... Mr. Doman will make a corporate ...
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... report is available in its catalogue: ... India Drug Forecast and Market Analysis to ... PharmaPoint: Atopic Dermatitis - India Drug ...
Breaking Medicine Technology:Intellectual Property Insurance for Medical-related Products and Services 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5
... 2010 MMRSS, which has been,expanding its geographic footprint over the past 5 years, announced the,opening of ... , , ... Thailand , Indonesia , Sri,Lanka , Bangladesh , Vietnam and UAE, has ... , , ...
... , SUNNYVALE, Calif. , Aug. 3 Accuray Incorporated ... field of radiosurgery, announced today it received Shonin approval from the Japanese ... Robotic Radiosurgery System to treat tumors non-invasively anywhere in the body, inclusive ... as the "CyberKnife® Radiosurgery System." , ...
Cached Medicine Technology:MMRSS now in Hong Kong, Singapore and Taiwan 2Accuray's CyberKnife® G4 System Receives Shonin Approval 2Accuray's CyberKnife® G4 System Receives Shonin Approval 3Accuray's CyberKnife® G4 System Receives Shonin Approval 4
(Date:4/17/2014)... University of California, San Diego School of Medicine report ... suffered a recent major loss are more likely to ... The study is published in this month,s issue of ... Because compassionate behaviors are associated with better health and ... into ways to improve the outcomes of individuals whose ...
(Date:4/17/2014)... has created a new technology for modifying human ... the body and selectively target cancer and other ... that monitor and modify human physiology is a ... existing technology enabled bioengineers to build such devices ... in a customized fashion. , "The project addressed ...
(Date:4/17/2014)... The cause of neuronal death in Parkinson,s disease ... neurons may be mistaken for foreign invaders and killed ... way autoimmune diseases like type I diabetes, celiac disease, ... was published April 16, 2014, in Nature Communications ... idea in Parkinson,s disease; but if true, it could ...
(Date:4/17/2014)... April 17, 2014 EcoHealth Alliance, a nonprofit organization ... published a comprehensive review today examining the current state ... The review calls for improved global surveillance strategies to ... recent outbreak of Ebola in West Africa that has ... of Guinea and Liberia. According to the World ...
(Date:4/17/2014)... YORK (17 April 2014) Population Council scientists and their ... safe, stable, and can prevent the transmission of multiple ... rectum in animals: HIV, herpes simplex virus 2 (HSV-2), ... the first data that the gel is effective against ... efficacy in the vagina against all three viruses of ...
Breaking Medicine News(10 mins):Health News:The ilk of human kindness 2Health News:Building 'smart' cell-based therapies 2Health News:Is Parkinson's an autoimmune disease? 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3Health News:Animal study provides first evidence that gel can prevent multiple virus transmission in vagina/rectum 2
... ... MILLS, Md., March 12 Medifast, Inc.,(NYSE: MED ) announced ... 31, 2007., Financial highlights included:, -- Annual revenues ... to the previous year,s fourth quarter; ...
... nodes could alter treatment approach, study suggests , , WEDNESDAY, ... tumors and tissue from patients with early-stage lung cancer ... say researchers at the Johns Hopkins Kimmel Cancer Center. ... approach for lung cancers, which recur within five years ...
... Call Scheduled for Thursday, March 13, 2008, LANCASTER, ... ) today reported financial results for the second quarter,ended ... weeks ended February 3, 2008 were,approximately $34.7 million. Net ... per share., Myron Levy, the Company,s Chairman and ...
... 12 Cadence Pharmaceuticals,Inc. (Nasdaq: CADX ), ... proprietary product candidates principally,for use in the hospital ... year ended December 31, 2007, and provided corporate ... and for 2008 to date., "During 2007, ...
... 12, 2008 (BRONX, NY) The unwanted activation ... in two kidney problems that are major causes of ... of Medicine of Yeshiva University have found. Their research, ... failure, is described in the March issue of Nature ...
... been awarded a five-year, $2.1 million grant from the ... of the National Institutes of Health (NIH), to continue ... on research careers. , The grant renews support that ... the training of 26 UI clinician-scientists in pediatrics. They ...
Cached Medicine News:Health News:Medifast Announces Year-end 2007 Financial Results 2Health News:Medifast Announces Year-end 2007 Financial Results 3Health News:Medifast Announces Year-end 2007 Financial Results 4Health News:Medifast Announces Year-end 2007 Financial Results 5Health News:Medifast Announces Year-end 2007 Financial Results 6Health News:Medifast Announces Year-end 2007 Financial Results 7Health News:Medifast Announces Year-end 2007 Financial Results 8Health News:Medifast Announces Year-end 2007 Financial Results 9Health News:Genetic Markers May Predict Lung Cancer Recurrence 2Health News:Herley Reports Second Quarter Results 2Health News:Herley Reports Second Quarter Results 3Health News:Herley Reports Second Quarter Results 4Health News:Herley Reports Second Quarter Results 5Health News:Herley Reports Second Quarter Results 6Health News:Herley Reports Second Quarter Results 7Health News:Herley Reports Second Quarter Results 8Health News:Herley Reports Second Quarter Results 9Health News:Herley Reports Second Quarter Results 10Health News:Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results and Provides Corporate and Clinical Program Overview 2Health News:Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results and Provides Corporate and Clinical Program Overview 3Health News:Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results and Provides Corporate and Clinical Program Overview 4Health News:Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results and Provides Corporate and Clinical Program Overview 5Health News:Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results and Provides Corporate and Clinical Program Overview 6Health News:Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results and Provides Corporate and Clinical Program Overview 7Health News:Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results and Provides Corporate and Clinical Program Overview 8Health News:Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results and Provides Corporate and Clinical Program Overview 9Health News:Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results and Provides Corporate and Clinical Program Overview 10Health News:Novel discovery by Einstein scientists could lead to much-needed kidney failure treatment 2Health News:$2.1 million NIH grant advances U-Iowa child health research 2Health News:$2.1 million NIH grant advances U-Iowa child health research 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: